Jinxin Shiny CACLP 2025: Non-magnetic bead nucleic acid extraction technology leads the new future of biological sample processing
The 22nd China International Inspection Medicine and Blood Transfusion Instrument and Reagent Expo (CACLP 2025) has come to a successful conclusion in 2025! As an annual event of the in vitro diagnosis industry, this exhibition brought together the world's top enterprises and showcased the most cutting-edge technologies and products.
Shanghai Gene Era Bio-Science Co., Ltd. made a stunning appearance with its core products such as biological sample processing, nucleic acid extraction and purification, laboratory consumables, etc., attracting the attention of hundreds of professional visitors from hospitals, third-party testing institutions, scientific research institutions, molecular testing enterprises, mass spectrometry enterprises and other fields.
Non-magnetic bead nucleic acid extraction technology has caused great repercussions
At this exhibition, the company showcased its innovative non-magnetic bead reverse adsorption nucleic acid extraction and purification product for the first time. Unlike conventional magnetic beads and centrifugal column methods, this product utilizes self-developed polymer materials for reverse nucleic acid extraction, significantly improving recovery rates and making it particularly suitable for handling extremely small sample volumes. Additionally, eliminating washing and centrifugation steps makes it ideal for outdoor and home environments. The technology generated significant buzz at the exhibition, with multiple leading molecular diagnostics companies expressing strong interest and reaching preliminary cooperation agreements with clients.
Bio-sample pretreatment technology leads to new hope of nucleic acid detection
With years of expertise in biological sample processing, the company has developed advanced techniques for separating target samples from host specimens and enriching ultra-rare samples. These innovations can boost nucleic acid detection efficiency by tens to hundreds of thousands of times. Having partnered with leading hospitals and research institutions, the company continues to pioneer new testing solutions. The technology has attracted widespread attention from industry peers, who have actively expressed interest in collaborative partnerships.
The whole series of high-end laboratory consumables are well received
High quality suction head, test tube and sample tube are enzyme-free and pyrogen-free to ensure the accuracy of the experiment.
Customer focus hotspots
Through in-depth communication with the live audience, we found that customers are particularly concerned about the following areas:
☑ Automation and high throughput: How to improve the efficiency of sample processing?
☑ Stability and cost control: How to optimize the cost while ensuring quality?
☑ Quick test requirements: How to shorten the nucleic acid extraction time and adapt to POCT scenarios?
In view of these needs, Jin Xin provides customized solutions, which have won high recognition from customers.
Core Advantages of Jin Xin
1. Technology Leadership: Independently developed with compatibility for multiple sample types (blood, tissue, FFPE, etc.).
2. Cost-Effectiveness: Compared to international brands, Jin Xin Bio maintains equivalent quality while offering more competitive pricing.
3. Comprehensive Services: Provides full-spectrum support including technical training, after-sales assistance, and customized development solutions.
At the show, we also observed the latest developments in the industry
Automation and intelligence: many enterprises have launched fully automatic nucleic acid extraction workstations to reduce manual operation.
Microfluidic technology: Some manufacturers demonstrate rapid detection schemes based on microfluidic, which are suitable for primary medical care.
Green environmental protection: degradable consumables have gradually become the focus.
Looking ahead, CACLP 2025 will not only be an exhibition, but also an opportunity for industry exchange and learning. In the future, Jinxin Biotech will continue to focus on sample pretreatment and molecular diagnostics, launch more innovative products, and contribute to the development of precision medicine!
Looking forward to working with you to create the future